ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.
about
Evolutionary dynamics of cancer in response to targeted combination therapyALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsPreclinical Murine Models for Lung Cancer: Clinical Trial ApplicationsFrom tissue to molecular phenotyping: pre-analytical requirements heidelberg experienceWill kinase inhibitors make it as glioblastoma drugs?Apoptotic agentsStereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategyIdentification of targetable FGFR gene fusions in diverse cancers.Systematic identification of combinatorial drivers and targets in cancer cell linesβ₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapyThe Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors.Open-access synthetic spike-in mRNA-seq data for cancer gene fusions.Transforming fusions of FGFR and TACC genes in human glioblastoma.Discovering and understanding oncogenic gene fusions through data intensive computational approachesUse of big data in drug development for precision medicine.Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity.A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.Evaluating translocation gene fusions by SNP array data.Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancerGenome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.Collateral Lethality: A new therapeutic strategy in oncologyIdentification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.Timing and heterogeneity of mutations associated with drug resistance in metastatic cancersMouse model for ROS1-rearranged lung cancerReceptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma.Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and TreatmentGeneration and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung.Molecular diagnosis of intrahepatic cholangiocarcinoma.Biomarkers for prognosis and treatment selection in advanced bladder cancer patients.An emerging toolkit for targeted cancer therapies.Translating cancer 'omics' to improved outcomes.PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsTyrosine kinase inhibitors in lung cancer.MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression.Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsPlatelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneityProof of concept to clinical confirmation: evolving clinical trial designs for targeted agents.Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perilsALK-immunoreactive neoplasms.
P2860
Q21128788-4EFCB050-3F20-433C-81D9-453C8EE6AD60Q26769879-24F6CEF0-3B67-4FC3-8092-750C784EF3D8Q26863474-8AC070E1-21C2-4B99-8ACD-B3BF89D39162Q26864637-9E23D1E5-9D96-450E-AF84-A72475BD880AQ27012684-6B3B3528-CE76-43D0-99C9-81701F991FCBQ27016160-8B03FFFC-FD64-4870-8CFF-FE1C2C166D2FQ27682798-7B0ED83C-EEAD-41DE-A243-7229172223B7Q27852147-511F90C8-1A1A-4EC2-AA58-A479B8DAB24FQ28486051-BDF10CA3-82E3-49CE-8425-3B54A219D98FQ30427521-E08454E0-E782-46EA-B1EF-EDC8E06118F8Q30486741-10668D4A-D2AB-482D-BAD8-67A2CDE31B02Q30487334-DD831444-5D1E-44B8-BF53-3002F3D8065DQ30540467-7D63DF27-986A-43CC-B405-4831F2A0B9EDQ31083417-A77ED7D7-175C-49DE-92C2-5DF5144DCE18Q31115480-796B155B-E1B9-4800-BA7C-D48188DAEB8DQ33636098-262007C7-C4C2-4C59-A5FE-EAB4C5A53017Q33776852-60308C0E-D473-45EA-B2FE-59F1439D4074Q33865475-24B23E07-71DB-47B6-9F6A-5DEB4B6548AFQ34132911-EB299E43-040E-4B7C-8D76-B8811493BC94Q34356166-D3248A56-4906-4FCA-904C-479CDADD5CA1Q34362370-7E470EAA-ABFF-410A-A325-8BEC7C6799DDQ34513800-E31AB7DF-6C7C-404C-9D90-AB35731C5F01Q34522899-D62822F7-DBC5-4CA5-B2D7-882448300AD7Q34525966-A3295C13-27CF-4C02-9FEE-1DCCDF3D3419Q34589721-31F3AFBF-A544-4CDA-9F24-EE70D4D9C6A0Q34633416-4B6BA9D2-D119-40CA-B467-0E91ADA96BD7Q34662576-4144798B-094A-4C70-8516-940B72F8CA93Q35287629-D8731EC7-34B4-40C1-9E52-33D07FB411B1Q35592221-F544C472-F924-45AD-910F-88D4D44AF31FQ35671292-5F5D0DB7-71B9-4578-90CB-9CE7CD4BF5F6Q35694357-8B6DDCA1-1818-489D-AC06-65003D0F468FQ35694365-448C5F89-F210-419A-91CF-5D7A110DB084Q35858617-AA45A184-2CF2-4910-804C-F21F33A707F8Q35908430-B5188891-1C46-4B88-BAC1-88BBEAAFDEEEQ35951821-B46198CD-8A6A-4EE9-9817-1CECC8CF66F4Q35967385-45A0B276-4842-43FF-BFEE-3F56C102BB77Q36020891-7D3BB73D-FC67-4EB6-8E64-230D62E49D9AQ36021866-2C3549E3-B978-4647-B6DE-C617C0AFD920Q36038823-ED2385E6-8E70-4A89-A722-4612DC49873BQ36092957-0833C915-729A-4B7F-95AD-70DC117DF650
P2860
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.
@ast
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.
@en
type
label
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.
@ast
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.
@en
prefLabel
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.
@ast
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.
@en
P2860
P1433
P1476
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.
@en
P2093
David E Gerber
John D Minna
P2860
P304
P356
10.1016/J.CCR.2010.11.033
P577
2010-12-01T00:00:00Z